Anemia and transfusion requirements among Ugandan children with severe malaria treated with intravenous artesunate

Michael T. Hawkes, Robert Opoka, Andrea L. Conroy, Robyn E. Elphinstone, Heather A. Hume, Sophie Namasopo, Kevin C. Kain

Research output: Contribution to journalArticle

Abstract

Parenteral artesunate for the treatment of severe malaria in non-immune travelers is associated with late-onset hemolysis. In children in sub-Saharan Africa, the hematologic effects of malaria and artesunate are less well documented. Here we report a prospective case series of 91 children with severe malaria treated with parenteral artesunate, managed at a resource-poor hospital in Africa, with longitudinal data on hemoglobin (Hb), lactate dehydrogenase (LDH), haptoglobin, and erythrocyte morphology. The median (range) age was 2 (1–8) years and 43 (47%) were female. The median (IQR) admission Hb level was 69 (55–78) g/L and 20 patients (22%) had severe malarial anemia (Hb 

Original languageUndefined/Unknown
JournalPaediatrics and Child Health, East Africa
DOIs
Publication statusPublished - 1 Dec 2019

Cite this